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Abstract
We present preliminary results that quantify network robustness and fragility of Ewing sarcoma (ES), a rare
pediatric bone cancer that often exhibits de novo or acquired drug resistance. By identifying novel proteins or
pathways susceptible to drug targeting, this formalized approach promises to improve preclinical drug devel-
opment and may lead to better treatment outcomes. Toward that end, our network modeling focused upon the
IGF-1R-PI3K-Akt-mTOR pathway, which is of proven importance in ES. The clinical response and proteomic net-
works of drug-sensitive parental cell lines and their drug-resistant counterparts were assessed using two small
molecule inhibitors for IGF-1R (OSI-906 and NVP-ADW-742) and an mTOR inhibitor (mTORi), MK8669, such
that protein-to-protein expression networks could be generated for each group. For the first time, mathematical
modeling proves that drug resistant ES samples exhibit higher degrees of overall network robustness (e.g., the
ability of a system to withstand random perturbations to its network configuration) to that of their untreated or
short-term (72-hour) treated samples. This was done by leveraging previous work, which suggests that Ricci cur-
vature, a key geometric feature of a given network, is positively correlated to increased network robustness. More
importantly, given that Ricci curvature is a local property of the system, it is capable of resolving pathway fragility.
In this note, we offer some encouraging yet limited insights in terms of system-level robustness of ES and lay the
foundation for scope of future work in which a complete study will be conducted.
1. Introduction
Quantifying the fragility and robustness of biological cell signaling pathways is a problem of paramount impor-
tance in guided targeted cancer therapy. In this note, we restrict our attention to Ewing sarcoma - which like many
cancer types - often circumvents the effect of drug therapies due to counter-regulatory signaling cascades. In ES,
compelling evidence has shown that the insulin-like growth factor 1 receptor (IGF-1R) is particularly important
[1, 2, 3, 4] as it is involved in the activation of multiple oncogenic pathways including the downstream activation of
phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (mTOR) [5]. To this end, studies have shown that
targeting IGF-1R can inhibit growth in ES cells in vitro, in xenograft models, and in 10-14% of ES patients who
had dramatic (albeit short-lived) clinical responses to IGF-1R Abs in clinical trials conducted since 2007 [6, 7].
As such, combinatorial inhibition of IGF-1R and mTOR has been shown to triple the response rate as compared to
sole IGF-1R inhibition [8, 9, 10, 11]. Although drug-resistant ES samples still arise, this noted synergistic effect
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with respect to duration of response lends support to notions of network “fragility” and “robustness” [12]. That
is, on the one hand, tumors can initially be quite fragile to dual IGF-1R/mTOR targeting while, on the other hand,
quickly acquire drug resistance, that manifests as robustness mediated by alternative feedback loops that promote
cell survival. This preliminary note lays the continued foundation to the follow key question:
Central Question: Given the complexity and cost of selecting drug candidates, can we quantify (and there-
fore predict) pathway fragility in order to uncover a set of a set of n-tuple targets that can properly disrupt the
alternative signaling cascades attributed to ES tumor growth?
In addressing this critical question, a host of new “-omics” technologies has provided cancer biologists with
unparalleled access to expression data across the proteome or transcriptome that allows scientific exploration of
tumor phenotype at the network level, rather than a reductionist approach confined to specific protein-protein in-
teractions. As such, one can consider cellular interactions apart of the interactome as a complex dynamical system
represented by weighted graphs [13, 14, 15, 16]. In doing so, we are able to compute certain geometric features
in hopes of elucidating certain key attributes and stylized facts of the underlying system. One such property is
the geometric notion of curvature [17]. We have previously shown that increased Ricci curvature is positively
correlated with increased robustness, herein expressed as ∆Ric ×∆R ≥ 0 [18]. Generally speaking, robustness
relates to the rate at which a given dynamical system returns to its original (normal) state following a perturbation
or external disturbance. Though essential for maintaining homeostasis in living organisms, as applied to cancer,
robustness can be interpreted as the ability of malignant cells to coopt or reshape signaling pathways in a way that
preserves cell survival despite perturbations induced by drug therapy. In practice, we note that malignant cells
may acquire robustness against some perturbations, and in so doing, unearth other areas of fragility that would
not otherwise have existed. This oncogene addiction can be exploited using biologically targeted therapies that
selectively kill cancer cells and belies the use of many of todays most effective oncology drugs.
We refer the reader to [12, 20, 21, 22] for a precise definition of robustness and several works [23, 24, 25, 26, 27]
regarding the details of curvature. Nevertheless, the key concept here is that on a given graph/interactome, we are
able to employ Ricci curvature to express system-level and pathway fragility. In the context of clinical success, it
has been argued that feedback loops are essential to the function of ES with previous rationale for the success of
joint IGF-1R/mTOR inhibition [5]. Stated in the context of graph theory, this feedback or the number of triangles
in an interactome (redundant pathways) can be characterized by a lower bound of Ricci curvature [18, 29, 30]. We
show some key pathways connected to IGF-R1 in Figure 1.
We previously demonstrated that cancer networks exhibit a higher degree of global robustness (in terms of net-
work curvature) in relation to their normal counterparts [18]. We now focus our attention on comparing robustness
for drug resistant, drug sensitive, 72-hour treated samples specifically in ES (treated by OSI-906/NVP-ADW-742
and MK8669) by constructing protein-to-protein correlation expression networks derived from a selected reverse
phase protein assay (RPPA) panel for each associative group. We note that the protein interaction topology may
change under selective pressure of chemotherapy, forging new protein-protein interactions that typically would
not exist physiologically. For simplicity, we fix the topology of the networks using prior data on known physical
interactions allowing only the weights to evolve. Then, by treating each network as a random walk (e.g., the
path traversed by a molecule as it travels in a liquid), we attempt to exploit the underlying dynamics of specific
protein-to-proteins interactions. Nevertheless, we caution readers on the current preliminary results due to the
limitation of sample size and scope of network pathways - this work is presented with the forethought that a
larger exploratory analysis will be conducted to ensure clinical benefit.
The remainder of the present note is outlined as follows: In the next section, we revisit a previously employed
method for measuring network and pathway fragility via Ricci curvature, in the Ollivier sense [28, 27]. Section 3
presents preliminary results demonstrating that resistant ES cell samples are more robust than their untreated
counterparts with drug sensitive samples being the most fragile; this is illustrated in Figure 2. We also elucidate
Figure 1. A simple schema of the IGF-1R pathway. IGF-1R is activated through binding of IGF-1 and IGF-2. Autophospho-
rylation and crosslinking of IGF-1R leads to activation of IRS-1 and Shc and from there downstream activation of PI3K/Akt
and Ras pathways.
Figure 2. Proposed behavior of ES cells to IGF-1R and mTOR blockades.
possible pathways (e.g., MEK1, IRS1, PI3K) that have been suggested as possible significance with regards to
contribution to the robustness in ES. We conclude with a discussion of future work.
2. Measuring Fragility via Ricci Curvature
As mentioned in the previous section, we utilize the stylized fact that increases in Ricci curvature are positively
correlated to increases in robustness, i.e., ∆Ric × ∆R ≥ 0. Given that our work is confined to a discrete space
of an interactome/graph in which the nodes on a graph represent a particular protein/gene and edges represent
an direct interaction, we employ a notion of a Ricci curvature [27] inspired through coarse geometry. That is,
in order to generalize Ricci curvature to a discrete space, certain properties of curvature are adopted from the
continuous setting. In this case, the intuition is that the transportation distance between two small (geodesic balls)
is less than the distance of their centers on a positively curved space, greater than distance of their centers on a
negatively curved space, and equal to the distance on a space of zero curvature. Specifically, if we let (X, d) be a
metric space equipped with a family of probability measures {µx : x ∈ X}, we define the Ollivier-Ricci curvature
κ(x, y) along the geodesic connecting nodes x and y via
W1(µx, µy) = (1− κ(x, y))d(x, y), (1)
Figure 3. Modeling the selection for a drug target candidate. An example of the complexity of choosing drug targets. Only
focusing on the mTOR signaling pathways, there exists a vast set direct interactions compounded further by the influence of
indirect interaction (e.g., mTOR to p38 MAPK via AKT). The resulting structures builds various feedback (not seen in this
figure) circumventing the effect of a particular therapy (e.g., series of interactions leading p38 MAPK back to mTOR) . The
methodology proposed in this note attempts to provide a solution that can quantify pathway fragility and robustness of such
indirect interactions. In turn, we can then begin to understand mechanisms of resistance
where W1 denotes the Earth Mover’s Distance (Wasserstein 1-metric) [31, 32] and d is the geodesic distance on
the graph. For the case of weighted graphs, we set
dx =
∑
y
wxy (2)
µx(y) :=
wxy
dx
, (3)
where dx is the sum taken over all neighbors of node x and where wxy denotes the weight of an edge connecting
node x and node y (wxy = 0 if there is no direct edge connecting node x to node y). The measure µx may be re-
garded as the distribution of a one-step random walk starting from x, with the weight wxy quantifying the strength
of interaction between nodal components or the diffusivity across the corresponding link (edge). Computation-
ally, the above term W1 may be computed as a linear program [33] allowing for several numerical advantages
[18]. From this, we can then measure the fragility of a given (not necessarily adjacent) pathway through de-
creases/increases in the term κ(x, y) with the hopes that such measures will be able to guide targeted therapies
through such biological complexity. An example of this complexity can be seen in Figure 3.
3. Results
In this section, we test this hypothesis using proteomic expression data taken from ES cells cultured in vitro and
present the resulting computation for network curvature/robustness related to IGF-1R and mTOR blockades in ES
cell lines.
3.1. Data and Network Construction
The preliminary data was obtained using protein expression data, measured via highly sensitive reverse-RPPA
in experiments conducted at MD Anderson that investigated mechanisms of resistance in TC32 and TC71 ES
cell lines to IGF-1R and/or mTOR inhibition [19]. Briefly, two independent methods were used to generate drug
resistance in ES cell lines grown in monolayer culture. In the first method, parental cell lines were exposed to
steadily increasing drug concentrations of OSI- 906 or NVP-ADW-742 for 7 months. In the second method, ES
cells were exposed to exceedingly high concentrations for 72 hours before selecting viable clones, which were
expanded. These two groups were combined along a set of parental samples; herein referred to as drug resistant
ES cell lines. The resulting drug-resistant cells were compared to untreated parental cells and to cells exposed to
Table 1. Global network results for IGF-1R treatment show that, on average, robustness as measured by Ricci curvature is
higher in drug resistant samples with drug sensitive samples being the most fragile. The analysis presented in this table
shows both average Ricci curvature, minimum curvature, and average value of the left tails (at specific lengths) in order to
characterize the “shifts” seen within each network.
the studied drugs for 72 hours; herein referred to as drug sensitive. A separate, but similar experiment was re-
peated with MK8669 to generate a complementary data set targeting the effects of mTOR inhibition. All together,
there consists a set of 12 drug resistant samples, 4 drug sensitive samples, and 8 parental (untreated) samples for
the OSI-906/NVP-ADW-742 (IGF-1R) treatment while 8 drug resistant samples, 2 drug sensitive samples, and 3
parental samples for the MK8669 (mTOR blockade) treatment were obtained. Using the RPPA protein expres-
sion data (consisting of a small set of 112 and 165 proteins for IGF-1R and mTOR experiments, respectively),
we were able to generate a protein-to-protein network through known physical interactions and with weights that
were computed from the correlation across such samples within each group. We should note that although the
OSI-906/NVP-ADW-742 targeting IGF-1R inhibition, the data examined does not include IGF-1R expression and
lacks several proteins of interest (due to experimental reasons conducted outside the scope of the present work).
However, the data analyzed for MK8669 treatment did include mTOR and adjacent interactions/proteins in this
cell-signaling pathway. Nevertheless, six ES networks characterizing the drug resistant, drug sensitive, and un-
treated cases for IGF-1R and separately, mTOR inhibition, were constructed and were sufficient for macroscopic
analysis.
3.2. Global Network and Pathway Fragility
Following our previous work [18], we conducted a global analysis with respect to network curvature on six
networks that emerged from each of the two drugs and three treatment states to highlight the inherent robustness
in ES resistant cell lines. In particular, Table 1 and Table 2 present the average Ricci curvature in each of the three
groups for samples treated with NVP-ADW-742/OSI-906 and MK8669 as well as average value of the left tails (at
given lengths of 5%, 3% and 1%). As such, one can see that the difference between drug resistant and untreated
(and/or drug sensitive) samples is positive signifying robustness. Moreover, the drug sensitive samples that were
only transiently exposed to IGF-1Ri and/or mTORi for 72 hours exhibited fragility when compared to the untreated
and resistant cases, mimicking the higher state of drug resistance observed clinically. In addition to the average
statistic, one can consider the left tail of the distribution as the lower bound of Ollivier-Ricci curvature as opposed
to simply taking minimum value which maybe sensitive to topological errors. The motivation for analyzing the
lower bound / left tails of the distribution is significant as it is intimately connected to a notion of entropy which
also serves as a proxy for robustness [18, 23]. While beyond the scope of this work, entropy is measure of the
number of specific ways in which a thermodynamic system may be arranged, and has been commonly understood
as a measure of disorder or randomness in a given system.
While global results provide a quantitative indicator of network robustness/fragility, the clinical benefit of the
above method is that the methodology measures fragility in pathways (that need not be necessarily directly con-
nected) for particular targets. We can analyze particular targets in varying manners, one of which is through scalar
Table 2. Global network results for mTOR inhibition via MK8669 also shows that, on average, robustness as measured by
Ricci curvature is higher in drug resistant samples with drug sensitive samples being the most fragile. The analysis presented
in this table shows both average Ricci curvature, minimum curvature, and average value of the left tails (at specific lengths)
in order to characterize the “shifts” seen within each network.
curvature [18]. Specifically, we define scalar curvature in this text as
S(x) =
∑
y
κ(x, y) (4)
which is simply the sum all Ricci curvature over direct and indirect pathways. The decision to employ this
definition as opposed to simply summing over direct interactions is due to the fact that we would like to measure
activity of a particular protein with respect to all other proteins in the context of robustness/fragility. Thus, unlike
differential expression, scalar curvature defined in this manner measures hidden effects due to the underlying
network. To this end, Table 3 and Table 4 present several different proteins and their scalar curvature under drug
resistant, drug sensitive, and untreated cases.
Table 3. Scalar curvature results for several possible targets in Ewing Sarcoma when samples were treated with OSI- 906 or
NVP-ADW-742, which are known to inhibit IGF-1R/IR-α and IGF-1R.
Interestingly, we observe in Table 3 those direct/indirect pathways involved with particular proteins, i.e., IRS1,
that are in the “neighborhood of” of IGF-1R and IR-α elicit an increase to their robustness from drug sensi-
tive samples to drug resistant samples. On the other hand, mTOR seems, for the most part, unaffected by OSI-
906/NVP-ADW-742 treatment as compared to the relative change in Table 4. This is in line with prior reports,
which suggest the single-agent IGF-1R directed therapies are rarely potent enough to completely inhibit mTOR
and its downstream effectors [36]. As seen in Figure 4, this direct quantitative effect from the treatment of MK8669
with regards to mTOR fragility is what one would expect when targeting a particular protein.
Moreover, several other insights are noted. In particular, treatment with MK8669 responds to an increase
activation of IRS1 as opposed to OSI-906/NVP-ADW-742. This is expected, as others have reported that mTORi
disturb the negative feedback loop upon IRS-1 by p70S6K [37, 38, 39, 40]. Another protein, PRAS40, apart
of the mTOR complex I (mTORC1), elicited an increase in fragility when treated with MK8669. Biologically,
this falls in line with previous understanding of mTORC1 sensitivity to such targeting. The opposite effects
were registered in IGF-1R samples providing further (yet very limited) evidence that mTOR serves as a powerful
feedback structure when solely inhibiting IGF-1R [5]. In short, while such results are very preliminary, much of
Figure 4. Quantification of network robustness and fragility in ES cells treated with mTOR inhibition. This illustrates the
increase in fragility of mTOR and the surrounding “neighborhood” as a result of the treatment of MK8669 for 72-hours.
Unfortunately, resistance becomes to build over time muted the the therapeutic effect of solely inhibiting mTOR.
the biological understanding seen in previous literature holds true in our analysis on curvature on this small set of
samples.
4. Future Work Summary
In the above analysis, there exists several limitations that will need to be addressed. First and foremost, the
sample size and RPPA panel of proteins are quite small and for any clinical benefit to arise, we must extend the
above analysis. Though the proteins selected within the RPPA panel represent only a small fraction of the entire
proteome, they are enriched for proteins linked to cancer (either oncogenes or tumor suppressors). This is both
a weakness and strength; while the networks are biased toward cancer-related pathways, enrichment ensures the
most important oncogenic pathways are comprehensively assessed. Second, though in silico computational anal-
ysis is cheap, preclinical drug testing platforms can be expensive to perform and replicate. A third limitation,
reported by our group and others, is that ES samples cultured within traditional monolayer surfaces are prone
to phenotypic drift that, over time, allows cells grown in long-term culture to diverge from the phenotype that
naturally exists in human tumors. Though the present study used standard tissue culture methods, future exper-
iments may benefit from the use of biomimetic three-dimensional (3D) tissue engineered ES tumors, pioneered
by our laboratory, that reliably maintains several key hallmarks of cancer (proliferation rate, morphology, etc.)
[34, 35, 19]. Despite these challenges, our results suggest a path forward that yields a powerful quantitative frame-
work that may be used to concretely measure whether therapies are exerting their intended destabilizing effect
upon cancer survival. Notably, while our focus was narrowly tailored toward the IGF-1R/mTOR pathways base
upon its unquestioned importance in ES, we have only tapped the surface of what is possible using our mathe-
matical model, and other pathways are likely to prove equally or more important. As we address additional and
heretofore-unexplored pathways in the context of robustness and fragility, we demonstrated that drug resistant
samples are more robust than untreated or drug sensitive samples. While this finding is intuitive, an accurate cal-
culation of robustness, as enabled by employing the concept of Ricci curvature to biological systems, may provide
new clues that help pinpoint an optimal approach to prevent or defeat drug-resistant ES.
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